Evidence map›Paper›PMID 42222394›Full record

ArticleFrontiers in oncology2026

Case Report: Lenalidomide as a novel maintenance therapy for metastatic follicular dendritic cell sarcoma.

Saarang Kashyap, Esha Sankhala, Jordan Ziegler, Rebecca Godin, Ivan Huang, James Heeter, Spencer Rosant, Kamlesh K Sankhala

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Saarang KashyapDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, United States.
Esha SankhalaUniversity of Queensland, Brisbane, QLD, Australia.
Jordan ZieglerPrecision Next Gen Oncology and Research Center, Los Angeles, CA, United States.
Rebecca GodinPrecision Next Gen Oncology and Research Center, Los Angeles, CA, United States.
Ivan HuangDepartment of Physiological Science, University of California, Los Angeles, Los Angeles, CA, United States.
James HeeterDepartment of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, CA, United States.
Spencer RosantDepartment of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, CA, United States.
Kamlesh K SankhalaDepartment of Biology, University of California, Los Angeles, Los Angeles, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Follicular dendritic cell sarcoma (FDCS) is a rare, low- to intermediate-grade malignancy arising from mesenchymal-derived follicular dendritic cells, which can also present with high-grade pathological features and may rapidly become fatal. Conventional therapeutic strategies, primarily consisting of surgical resection with adjunctive systemic chemotherapy, such as gemcitabine-docetaxel, ifosfamide, doxorubicin, or other regimens, remain inconsistently effective, with median survival notably reduced in advanced or recurrent disease. Given the limited therapeutic options and frequent relapse, there is a critical need for well-tolerated treatments that can improve long-term outcomes for patients with metastatic FDCS. Here, we report the first documented clinical use of the immunomodulatory agent lenalidomide (Revlimid) as maintenance therapy for FDCS following chemotherapy. Remarkably, the patient achieved nearly total sustained remission with exceptional disease stabilization for approximately seven years, experiencing only one manageable recurrence. This clinical response points to lenalidomide as a promising maintenance therapy for metastatic FDCS and may provide further basis for consideration of lenalidomide as a refractory treatment.

Indexed as

follicular dendritic cell sarcoma (FDCS)immunomodulatoryimmunotherapylenalidomidemaintenance therapy (MT)metastatic

Identifiers

PMID42222394
PMCPMC13215918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.